24.8±23.9%, P<0.05). There were no statistically significant correlations between the levels of baseline Background. ACE polymorphism, especially genotype DD or D allele, may be involved in the progression of proteinuria and albuminuria and the magnitudes of the reduction of proteinuria and albuminuria under diabetic nephropathy. It may also have different effects on the reduction of proteinuria by ACE inhibitors in ACE inhibition (P>0.05).
Introduction
measured. Patients were classified into three groups in accordance with ACE genotypes (17 DD; 33 ID; 33 II ) and prospectively followed up for 3 months. Angiotensin-converting enzyme (ACE) inhibitors are Various clinical parameters including age, DM dura-the first line drugs for the therapy of hypertension tion, body mass index (BMI ), 24-h urine sodium, associated with diabetes in that they not only lower protein and albumin, BUN, serum creatinine, creatin-systemic blood pressure but also affect renal haemoine clearance (Ccr), mean arterial pressure (MAP), dynamic changes. Imanishi et al. [1] showed that the and HbA 1c
were measured in the pre-and post-mechanism by which an ACE inhibitor caused shorttreatment periods. ACE genotypes were determined by term decrease in albuminuria in early diabetic nephropolymerase chain reaction.
urinary excretion of sodium, protein and albumin, BUN, of factors: the type or the dose of ACE inhibitors, the serum creatinine, creatinine clearance (Ccr), mean arterial duration of therapy, the level of sodium intake, and pressure (MAP), and HbA 1c were measured in the pre-and the type of the patient's ACE genotype [9] [10] [11] [12] . The post-treatment periods (3 months). During the 3-month ACE in the renin-angiotensin system affects the cardio-study period, patient medication was not changed. Dietary vascular system through angiotensin II formation and intake for sodium was also not changed during the study inactivation of bradykinin. The ACE gene is located period. on the long arm of chromosome 17. Insertion or deletion of any of the 287 base pair fragments in the 16th intron of the ACE gene may determine its geno-Methods type. These genotypes in turn are used to characterize the polymorphism as II, ID or DD type. Recently it Specimen collection has been reported that each of these genotypes appeared to be a major determinant of plasma and After a 12-h overnight fast, 5 ml of EDTA-anticoagulated tissue ACE activities [13, 14] . antiproteinuric response to ACE inhibition. The anti-at baseline and 3-month follow-up periods. The mean of the proteinuric mechanism of ACE inhibitors are thought two measurements was taken. to decrease glomerular capillary pressure by reducing both efferent renal arteriolar resistance and systemic Measurements of serum and urine parameters blood pressure [15, 16 ] .
In the present study we investigated the antipro- 
Determination of ACE genotypes

Subjects and methods
For determination of I/D polymorphism of ACE gene,
Subjects
genomic DNA was extracted from peripheral blood leukocytes. A 287-bp I/D polymorphism in the intron 16 of the Eighty-three NIDDM patients with overt proteinuria (mean ACE was examined by polymerase chain reaction (PCR). value of the urinary protein excretion over 500 mg/day in PCR was performed according to the method of Tiret et al. the baseline status) were recruited from the Renal Clinic of [17] . The sequences of the sense and the antisense primers the Department of Medicine at Yongdong Severance were 5∞-CTGGAGAC-CACTCCCATCCTTTCT-3∞ and Hospital, Yonsei University College of Medicine from 5∞-GATGTGGCCATCACAT-TCGTCAGAT-3∞ respectSeptember 1997 to August 1998. They were classified into ively. PCR was performed in a final volume of 20 ml that three groups in accordance with their ACE genotypes (17 contained 200 ng of genomic DNA, 0.5 mmol of each primer, DD; 33 ID; 33 II ). They were prospectively followed up for 0.25 mmol/l dNTP, 1.5 mmol/l MgCl 2 , 50 mmol/l KCl, 3 months. All were Korean. Before enrollment in the study, 10 mmol/l Tris-HCl (PH 8.4), and 1 U Taq DNA polyall the patients signed informed consent forms. Previously merase. Amplification was carried out for 35 cycles with used ACE inhibitors were withdrawn for at least 2 weeks steps of denaturation at 94°C for 2 min, annealing at 58°C before the study and baseline proteinuria and albuminuria for 15 s, and extension at 72°C for 30 s. The PCR products were measured using a 24-h urine collection. Each patient were subjected to electrophoresis in 1.5% agarose gels and provided two 24-h urine collections. The mean values of the stained by ethidium bromide for visualization. To avoid two measurements were taken as the baseline data. We mistyping of the ID genotype as DD, we repeated the resumed previously used ACE inhibitors with fixed dose genotyping procedure with DD genotype. (benazepril 10 mg/day or perindopril 4 mg/day). Ten of the 17 DD patients, 15 of the 33 ID patients, and 18 of the 33 II patients were treated with benazepril. The remaining Statistical analysis patients were placed on perindopril. There was no specific reason for choosing one ACE inhibitor over the other in a All data are presented as mean±SD except urinary protein and albumin. A one-way ANOVA test was used to analyse given patient. Blood pressures were measured by sphygmomanometer in a sitting position, and a mean of two consecut-between-group and within-group differences. A paired Student's t-test was used to test for differences between the ive blood pressure reading was recorded. Mean arterial pressure (MAP) was calculated as the sum of two-thirds of baseline values and those after ACE inhibition therapy.
Variables with skewed distributions (e.g. BUN, creatinine) the diastolic and one-third of the systolic blood pressure. A diagnosis of hypertension was made if the patient had two were logarithmically transformed and then tested by Student's t-test. Concomitantly, the non-parametric consecutive blood pressure readings >140/90 mmHg or if mean arterial pressure was >105 mmHg. Various clinical Mann-Whitney U tests were used to analyse variables with skewed distributions in spite of logarithmic transformations parameters including age, gender, DM duration, BMI, 24-h (e.g. urinary protein and albumin excretion). Statistical signi-significant differences between baseline values of proficance was assumed at a 5% level.
tein and albumin excretion and values of protein and albumin excretion after ACE inhibitions (P<0.05). Also, the percentage reduction of 24-h urinary Figure 3) . To exclude the possibility The distribution of ACE genotypes and allele frequen-that the patients with the greater baseline proteinuria cies were not different from a normal Korean popula-and albuminuria had the greater decreases of protion [18] . Table 1 shows baseline characteristics of teinuria and albuminuria following ACE inhibition, patients before initiating ACE inhibitors. There were we compared the baseline values of proteinuria and no significant differences in the clinical parameters albuminuria and the percentage reduction of prosuch as age, gender, body mass index (BMI ), DM teinuria and albuminuria after ACE inhibition. There duration, BUN, serum creatinine, HbA 1c
, % of hyper-was no statistically significant correlation between the tension, mean arterial pressure (MAP), creatinine levels of baseline proteinuria and albuminuria and the clearance (Ccr), and 24-h urinary excretions of sodium magnitudes of the reduction of proteinuria and albuamong three groups (P>0.05) ( Table 1) . However, the minuria after ACE inhibition (Figure 4) . These findmedian values of 24-h urinary protein excretion in the ings suggest that the amount of baseline proteinuria three genotype groups were significantly different (1152 and albuminuria do not affect the magnitude of the (182-6580) mg/day in DD vs 628 (204-4752) mg/day percentage reduction of proteinuria and albuminuria in ID and 666 (162-3600) mg/day in II, P<0.05). after ACE inhibition. Also, there were statistically significant differences in the level of median albumin excretion among the three Discussion groups (1010 (18-4958) mg/day in DD vs 289 (13-3596) mg/day in ID and 330 (56-3358) mg/day in II, P<0.05). After the 3-month treatment using In the present study, we evaluated whether the effects of short-term ACE inhibition on proteinuria, albumin-ACE inhibitors, there were no significant differences in the reduction of blood pressure and creatinine uria, blood pressure, and renal haemodynamics were affected by the ACE genotypes in proteinuric NIDDM clearance among the three groups (P>0.05) ( Table 2) .
Short-term 3-month ACE inhibition resulted in sig-patients. We found that patients with DD genotype are more susceptible to the antiproteinuric effect of nificant reductions of proteinuria and albuminuria in all three genotype groups. The magnitude of the ACE inhibition than those with II or ID. Interest in the role of ACE genotype in the progression of renal responses varied between individuals. The individual responses of proteinuria and albuminuria are shown disease has been raised by several recent studies and the rate of long-term renal function loss has been in Figures 1 and 2 , respectively. There were statistically found to be more rapid in patients with the DD patients with ACE gene DD genotype after 1 year of treatment with ACE inhibitors, but not in patients genotype than those with II or ID. This was found in patients with IgA nephropathy [19] , diabetic nephro-with the ID or II genotypes. Our present study in NIDDM patients with overt proteinuria concurs with pathy in IDDM [20] , as well as NIDDM [21] , and in a population of patients with non-diabetic renal the result of Yoshida et al. [19] in that the ACE gene DD may have a significant role in the antiproteinuric disorders of diverse aetiology [22] . In IgA nephropathy, Yoshida et al. [19] reported that a significant effect of the ACE inhibitors. Moriyama et al. [9] also studied 36 patients with various renal disorders, and decrease in urinary protein excretion was observed in genotype showed the fastest rate of albumin excretion rate (AER) progression on placebo but had an enhanced response to lisinopril. AER at 2 years was 51.3% lower on lisinopril than on placebo in the II genotype patients (P=0.01), 14.8% in the ID group (P=0.2), and 7.7% in the DD group (P=0.7). Jacobsen et al.
[24] also reported the antiproteinuric effect of ACE inhibition in 60 IDDM patients with diabetic nephropathy. They examined the potential role of an I/D polymorphism of the ACE gene on the early antiproteinuric responsiveness in an observational follow-up study and concluded that hypertensive albuminuric IDDM patients with the II genotype were particularly susceptible to renoprotective therapy. Our present observation does not coincide with EUCLID ACE I/D polymorphism is a strong predictor of ACE inhibition-associated renoprotection, in that proteinuria, D GFR, and a progression to ESRD are found impaired antiproteinuric response to ACE effectively reduced in patients with the DD, but not in inhibition in patients with the II genotype. This study, those with the II or ID genotype [25] . Our study however, included a small number of patients with concurs with the result of REIN trial, in that the ACE the DD genotype, a feature that is characteristic of gene DD may have a significant role in the antiproNorthern Asians. Not only the difference in study teinuric effect of the ACE inhibitors. population, but also difference in study design preclude
The antiproteinuric effect of ACE inhibitors has a straightforward comparison of their data with ours.
been thought to be independent of its antihypertensive Recently the EUCLID trial examined the effect of effect on the systemic blood pressure. In this study we the ACE I/D polymorphism on the antiproteinuric did not find any significant differences in MAP fall responsiveness to ACE inhibition in a randomized, among the three genotype groups. However, the antidouble-blind, placebo-controlled study of lisinopril proteinuric effect of ACE inhibition in DD genotype (10 mg/day) in 530 normotensive IDDM patients with normo-or microalbuminuria [23] . Patients with II was pronounced compared to II or ID genotypes. An I/D polymorphism of the ACE gene has been shown teinuria, and albuminuria after ACE inhibitions ( Figure 4 ). These findings suggest that the amount of to influence the ACE level in circulation and tissue. It has been thought that the ACE gene polymorphism baseline proteinuria and albuminuria does not affect the magnitude of the percentage reduction of procorrelates with the tissue ACE levels and thus determines the local angiotensin II and bradykinin teinuria and albuminuria after ACE inhibition.
In conclusion, the results of the present study show availability [13, 14] . Therefore we could expect that ACE gene D allele is associated with the higher avail-that the antiproteinuric effect of ACE inhibitors in DD genotype is significantly higher than that in ID and II ability of angiotensin II and the lower availability of bradykinin in the kidney. One can speculate that the genotypes. As to the distribution of allele D and I, allele I is more frequent than allele D. This result ACE gene D allele is associated with a higher efferent arteriolar resistance, resulting in a higher intra-corresponds with reports from China and Japan, unlike those of Europe or USA, suggesting an ethnic differglomerular pressure. In such a case, the vasodilatory effect of ACE inhibition on the efferent arteriole may ence [18] . This study suggests a potential role of the ACE genotype DD as a determinant of responsiveness be more pronounced. However, this speculation needs further clinical and experimental observation [1] .
to the antiproteinuric effect of ACE inhibition in NIDDM patients with overt proteinuria. However, There was a possibility that the antiproteinuric effect of ACE inhibitors has also been shown to be strongly further long-term and large-scale studies are required to confirm the issues regarding the mechanisms affected by the sodium intake, since a 50% reduction of proteinuria during 50 mmol sodium intake could be underlying this observed association. abolished almost completely by RAS suppression by a 200 mmol sodium intake [12, 26 ] . In our study, dietary sodium intake was not changed during the study period References and sodium excretion was similar among three genotype groups after ACE inhibition. There was another uria and the magnitudes of the reduction of pro-
